Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
EW 
Edwards Lifesciences Corp (EW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
02/25/2026: EW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
32 Analysts rated it
Highly popular stock, broad analyst coverage, trusted insights, strong investor interest.
1 Year Target Price $96.46
1 Year Target Price $96.46
| 10 | Strong Buy |
| 4 | Buy |
| 17 | Hold |
| 0 | Sell |
| 1 | Strong Sell |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 48.96B USD | Price to earnings Ratio 46.08 | 1Y Target Price 96.46 |
Price to earnings Ratio 46.08 | 1Y Target Price 96.46 | ||
Volume (30-day avg) 32 | Beta 0.94 | 52 Weeks Range 65.94 - 87.89 | Updated Date 02/25/2026 |
52 Weeks Range 65.94 - 87.89 | Updated Date 02/25/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.81 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-02-10 | When - | Estimate 0.6196 | Actual 0.58 |
Profitability
Profit Margin 17.69% | Operating Margin (TTM) 23.59% |
Management Effectiveness
Return on Assets (TTM) 7.72% | Return on Equity (TTM) 10.42% |
Valuation
Trailing PE 46.08 | Forward PE 27.86 | Enterprise Value 41641615000 | Price to Sales(TTM) 8.07 |
Enterprise Value 41641615000 | Price to Sales(TTM) 8.07 | ||
Enterprise Value to Revenue 7.32 | Enterprise Value to EBITDA 22.78 | Shares Outstanding 580300000 | Shares Floating 578524282 |
Shares Outstanding 580300000 | Shares Floating 578524282 | ||
Percent Insiders 1.42 | Percent Institutions 91.2 |
Upturn AI SWOT
Edwards Lifesciences Corp
Company Overview
History and Background
Edwards Lifesciences Corp. was founded in 1958 by Miles Edwards. Originally part of American Hospital Supply Corporation, it was spun off in 1999. The company is a global leader in artificial heart valves and hemodynamic monitoring. Key milestones include the development of the first successful artificial heart valve and pioneering transcatheter heart valve replacement therapies (TAVR).
Core Business Areas
- Heart Valve Therapy: Focuses on surgical and transcatheter heart valve replacement and repair technologies, including artificial heart valves, annuloplasty rings, and delivery systems for TAVR. This segment also includes diagnostic and monitoring devices for assessing valve function.
- Critical Care and Monitoring: Provides advanced hemodynamic monitoring systems and sensors designed to help clinicians optimize patient care in critical care settings, such as the operating room and intensive care unit. This includes devices for measuring blood flow, pressure, and other vital physiological parameters.
Leadership and Structure
Edwards Lifesciences is led by a management team that includes a CEO, CFO, and heads of various divisions. The company operates through distinct business segments, with a focus on research and development, manufacturing, and commercialization of its medical technologies.
Top Products and Market Share
Key Offerings
- Description: A leading transcatheter aortic valve replacement (TAVR) system designed for patients with severe aortic stenosis who are at high or extreme risk for open-heart surgery. It involves a balloon-expandable valve delivered via a catheter. Competitors include Medtronic (CoreValve/Evolut) and Boston Scientific (LOTUS Edge, though less prominent). Market share is estimated to be significant, often cited in the range of 40-50% of the global TAVR market, with strong revenue contributions.
- Product Name 1: Edwards SAPIEN Transcatheter Heart Valve System (TAVR)
- Description: A transcatheter edge-to-edge repair (TEER) system for mitral and tricuspid valve regurgitation. It allows for minimally invasive repair of leaky heart valves. Competitors include Abbott (MitraClip) and Boston Scientific (TEER devices). This is a growing market segment for Edwards, aiming to capture share from established players.
- Product Name 2: Edwards PASCAL Precision Edge System (TEER)
- Description: A disposable hemodynamic monitoring system that provides continuous, real-time measurement of cardiac output and other vital parameters. Used in critical care settings. Competitors include PiCCO and LiDCO. This product contributes to the Critical Care and Monitoring segment's revenue.
- Product Name 3: FloTrac System
Market Dynamics
Industry Overview
The medical device industry, particularly in cardiovascular and critical care, is characterized by rapid technological innovation, stringent regulatory oversight, and a growing demand driven by an aging global population and increasing prevalence of cardiovascular diseases. Key trends include minimally invasive procedures, personalized medicine, and digital health integration.
Positioning
Edwards Lifesciences is a leading player in the structural heart market, particularly in TAVR, holding a strong competitive advantage due to its early innovation and established product portfolio. The company is well-positioned to capitalize on the growth of TAVR and TEER procedures due to its robust R&D pipeline and strong clinical evidence. Its expertise in advanced hemodynamic monitoring also gives it a solid footing in the critical care segment.
Total Addressable Market (TAM)
The global structural heart market, which includes TAVR, TEER, and other interventional cardiology devices, is projected to reach tens of billions of dollars in the coming years, driven by increasing diagnosis rates and adoption of less invasive treatments. Edwards Lifesciences, with its leading position in TAVR and expanding TEER offerings, is strategically positioned to capture a substantial portion of this TAM.
Upturn SWOT Analysis
Strengths
- Market leadership in TAVR.
- Strong R&D pipeline and innovation capabilities.
- Established global distribution and sales network.
- Reputation for high-quality, reliable medical devices.
- Deep clinical expertise and strong relationships with healthcare professionals.
Weaknesses
- Reliance on a few key product lines.
- High cost of some innovative technologies can limit accessibility.
- Potential for regulatory hurdles and delays in product approvals.
- Competition is intensifying, especially in emerging markets.
Opportunities
- Expansion of TAVR and TEER into new patient populations and geographies.
- Development of next-generation valve technologies.
- Growth in emerging markets with increasing healthcare access.
- Leveraging data and digital health for improved patient outcomes.
- Potential for strategic acquisitions to expand portfolio.
Threats
- Increased competition from established and new players.
- Price pressures from healthcare systems and payers.
- Changes in reimbursement policies.
- Adverse clinical trial results or product recalls.
- Macroeconomic downturns impacting healthcare spending.
Competitors and Market Share
Key Competitors
- Medtronic plc (MDT)
- Abbott Laboratories (ABT)
- Boston Scientific Corporation (BSX)
Competitive Landscape
Edwards Lifesciences holds a dominant position in the TAVR market, but faces intense competition from Medtronic, which also has a significant market share with its Evolut platform. Abbott and Boston Scientific are also actively competing, particularly in the TEER space. Edwards' advantage lies in its pioneering role, strong clinical data, and established relationships, while competitors leverage their broad portfolios and aggressive R&D.
Major Acquisitions
CardioKinetix
- Year: 2016
- Acquisition Price (USD millions):
- Strategic Rationale: Acquired certain assets and intellectual property to bolster its transcatheter mitral valve technology portfolio, aiming to expand beyond aortic valve interventions.
Harpoon Medical
- Year: 2017
- Acquisition Price (USD millions): 125
- Strategic Rationale: Acquired to strengthen its position in transcatheter edge-to-edge repair (TEER) of the mitral valve, adding to its portfolio of minimally invasive structural heart solutions.
Growth Trajectory and Initiatives
Historical Growth: Edwards Lifesciences has experienced substantial historical growth, largely fueled by the successful adoption of its transcatheter heart valve technologies and the expansion of its market reach. The transition from surgical valves to TAVR has been a key driver.
Future Projections: Analyst projections for Edwards Lifesciences typically indicate continued strong revenue growth, driven by the expanding TAVR and TEER markets. The company is expected to benefit from an aging population and the ongoing shift towards less invasive cardiac procedures. Future growth is also anticipated from pipeline products and international expansion.
Recent Initiatives: Recent initiatives include the development and launch of next-generation TAVR and TEER devices, expansion of clinical trials to broaden indications, and strategic partnerships to enhance global market access. The company is also investing in digital health solutions to improve patient monitoring and care.
Summary
Edwards Lifesciences is a strong leader in the high-growth structural heart market, particularly with its pioneering TAVR technology. Its robust R&D, established market presence, and expanding product portfolio position it well for continued success. However, increasing competition, pricing pressures, and regulatory complexities are key areas to monitor. Sustaining innovation and expanding into new therapeutic areas will be crucial for its long-term growth and market dominance.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Investor Relations website (SEC filings, annual reports)
- Industry research reports (e.g., market intelligence firms)
- Financial news outlets (e.g., Wall Street Journal, Bloomberg)
- Medical device industry publications
Disclaimers:
This JSON output is for informational purposes only and does not constitute financial advice or a recommendation to buy or sell any securities. Market share data and financial figures are estimates and may vary based on reporting period and source. Actual market share and financial performance may differ from the information provided.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Edwards Lifesciences Corp
Exchange NYSE | Headquaters Irvine, CA, United States | ||
IPO Launch date 2000-03-27 | CEO & Director Mr. Bernard J. Zovighian | ||
Sector Healthcare | Industry Medical Devices | Full time employees 15800 | Website https://www.edwards.com |
Full time employees 15800 | Website https://www.edwards.com | ||
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. The company offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband brands. It also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.